Objective: The aim of this paper was to identify a simple screening measure for detecting metabolic syndrome (MetS) in people with schizophrenia and schizoaffective disorders.
Method: A total of 202 patients with chronic schizophrenia and schizoaffective disorders on antipsychotic medications were assessed for MetS using the criteria defined by the International Diabetes Federation. Receiver operating characteristic (ROC) analysis was applied using body mass index (BMI) as the test variable for diagnosis of MetS.
Results: The prevalence of MetS was 69.3%. Logistic regression analysis identified BMI and gender as significant predictors of MetS. ROC analysis identified BMI >28.7 as the criterion value with highest accuracy in terms of specificity and sensitivity. The likelihood ratios were robust at this cut-off score. The area under the curve was 0.75.
Conclusion: BMI is a quick and easy measure, and can be used as a screening test for MetS in any clinical or community setting.
MarderSREssockSMMillerAL. Physical health monitoring of patients with schizophrenia. American Journal of Psychiatry2004; 161: 1334–1349.
2.
SacksFM. Metabolic syndrome: Epidemiology and consequences. Journal of Clinical Psychiatry2004; 65(Suppl. 18)3–12.
3.
MeyerJMNasrallahHAMcEvoyJP. The Clinical Antipsychotic trials of Intervention Effectiveness (CATIE) Schizophrenia Trial: Clinical comparison of subgroups with and without the metabolic syndrome. Schizophrenia Research2005; 80: 9–18.
4.
ToalsonPAhmedSHardyTKabinoffG. The metabolic syndrome in patients with severe mental illnesses. Journal of Clinical Psychiatry2004; 6: 152–158.
5.
ClarkNG. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care2004; 27: 596–601.
6.
LambertTJRChapmanLH. Diabetes, psychotic disorders and antipsychotic therapy. Medical Journal of Australia2004; 181: 544–548.
7.
StrakerDCorrellCUKramer-GinsbergE. Cost-effective screening for the metabolic syndrome in patients treated with second-generation antipsychotic medications. American Journal of Psychiatry2005; 162: 1217–1221.
8.
American Psychiatric Association. Diagnostic Statistical Manual of Mental Disorders4th edn. Washington, DC: American Psychiatric Association, 1994.
WirshingDA. Schizophrenia and obesity: Impact of antipsychotic medications. Journal of Clinical Psychiatry2004; 65(Suppl. 18)13–26.
13.
SenguptaSMKlinkRStipEBaptistaTMallaAJooberR. Weight gain and lipid metabolic abnormalities induced by olanzapine in first-episode, drug-naïve patients with psychotic disorders. Schizophrenia Research2005; 80: 131–133.
14.
DeeksJJAltmanDG. Diagnostic tests 4: Likelihood ratios. British Medical Journal2004; 329: 168–169.
15.
SackettDLStrausSRichardsonWSRosenbergWHaynesRB. Evidence-Based Medicine. How to Practise and Teach EBM2nd edn. Churchill Livingstone, Edinburgh2000.
